FAQs
What is the response rate for sacituzumab govitecan? ›
Sacituzumab govitecan gave 35% objective response, which was 5% with chemotherapy. Neutropenia was among the treatment-related grade 3 or higher adverse events, the incidence of which was higher in the sacituzumab govitecan arm.
What is the success rate of sacituzumab govitecan? ›In clinical trials, sacituzumab govitecan has demonstrated high efficacy. In the IMMU-132 trial, the ORR was found to be 33.3% including complete response in three patients. The clinical benefit rate, including stable disease for >6 months was 45.4%.
Is sacituzumab govitecan approved by the FDA? ›On February 3, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for patients with unresectable, locally advanced or metastatic, hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+ with a negative in situ hybridization test) breast ...
What are the results of sacituzumab govitecan clinical trial? ›Sacituzumab govitecan (SG), a first-in-class anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over single-agent chemotherapy (treatment of physician's choice [TPC]) in patients with metastatic triple-negative breast cancer (mTNBC) in the international, multicenter ...